Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study.
The aim of the study was to assess the potential role of glucocorticoids (GC) in modulating systemic and pulmonary inflammatory responses in mechanically ventilated patients with severe pneumonia. Twenty mechanically ventilated patients with pneumonia treated at a respiratory intensive care unit (RICU) of a 1,000-bed teaching hospital were prospectively studied. All patients had received prior antimicrobial treatment. Eleven patients received GC (mean+/-SD dose of i.v. methylprednisolone 677+/-508 mg for 9+/-7 days), mainly for bronchial dilatation. Serum and bronchoalveolar lavage fluid (BALF) tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and C-reactive protein levels were measured in all patients. The inflammatory response was attenuated in patients receiving GC, both systemically (IL-6 1,089+/-342 versus 630+/-385 pg x mL(-1), p=0.03; C-reactive protein 34+/-5 versus 19+/-5 mg x L(-1), p=0.04) and locally in BALF (TNF-alpha 118+/-50 versus 24+/-5 pg x mL(-1), p= 0.05; neutrophil count: 2.4+/-1.1 x 10(9) cells x L(-1) (93+/-3%) versus 1.9+/-1.8 x 10(9) cells x L(-1) (57+/-16%), p=0.03). Four of the 11 (36%) patients receiving GC died compared to six (67%) who were not receiving GC (p=0.37). The present pilot study suggests that glucocorticoids decrease systemic and lung inflammatory responses in mechanically ventilated patients with severe pneumonia receiving antimicrobial treatment.
Montón
C
C
Serveis de Pneumologia i Al.lérgia Respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.
Ewig
S
S
Torres
A
A
El-Ebiary
M
M
Filella
X
X
Rañó
A
A
Xaubet
A
A
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D016084:Bronchoconstriction / Q000187:drug effects; D002097:C-Reactive Protein / Q000378:metabolism; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006784:Hospitals, Teaching; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007249:Inflammation / Q000276:immunology; D007275:Injections, Intravenous; D007375:Interleukin-1 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007958:Leukocyte Count; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009504:Neutrophils / Q000473:pathology; D010865:Pilot Projects; D018410:Pneumonia, Bacterial / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D011446:Prospective Studies; D012121:Respiration, Artificial; D012124:Respiratory Care Units; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D008775:Methylprednisolone